DILON Diagnostics and GE Healthcare are pleased to announce that they have signed an agreement for DILON to distribute GE's Discovery NM750b Molecular Breast Imaging system in select geographies across the globe. The signing of this distribution agreement will provide Dilon's experienced distribution network access to GE's Discovery NM750b Molecular Breast Imaging system and is considered an initial step in an ongoing exploration of ways to provide better healthcare solutions for clinicians and their patients.

The Discovery NM750b breast imaging system, designed to provide significant enhancement in lesion detectability, offers clinicians an important tool for imaging of a broad range of patients, including those with dense breast who may be at higher risk for breast cancer. The power of functional imaging to see early changes is a key factor in early detection in breast cancer.

"We are very pleased to associate with GE Healthcare, a world leader in innovation, in the fight against breast cancer," said Dr Robert G Moussa, DILON Diagnostics chairman and CEO. "This relationship will enable us to expand our product portfolio and offer a complete spectrum of BSGI/MBI solutions to better meet the needs of our customers."

"We are excited to make the Discovery NM750b breast imaging system further available and to benefit from DILON's global and solid network of sales representatives," said Mr Nathan Hermony, Nuclear Imaging global business manager for GE Healthcare. "GE believes strongly in this advanced technology and the potential for this type of imaging to improve breast cancer diagnosis. DILON Diagnostics resources will bring further the education and acceptance of Molecular Breast Imaging," he adds.